Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and the efficacy of the association of
Melphalan/Prednisone/Thalidomide/VELCADE (MPTV) as salvage treatment in advanced and
refractory myeloma patients. This association might further increase the response rate
achieved by the standard oral MP regimen.